Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20110811007297N5
IRCT20110811007297N5
Recruiting
Phase 3

: A randomized, tripple blind, controlled, clinical trial effect of simple zofa (hyssopus officinalis) syrup on persistant asthma

Shiraz University of Medical Sciences0 sites60 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Shiraz University of Medical Sciences
Enrollment
60
Status
Recruiting
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •older than 18 years old patients
  • •confirm of disease by internist. diagnosis criteria: acording to NAEP EPR3 criteria for persistant asthma disease: FEV1: 60\-80%

Exclusion Criteria

  • •history of allergy to plant of mint family
  • •dissatisfaction of treatment in each stage
  • •side effect development through treatment
  • •theophylline cosumption
  • •diabetic patients
  • •convulsion history
  • •pregnant patients
  • •patienta that need to hospitalize
  • •Exacerbation at beginning of study
  • •diability in statement of symptom intensity

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
OM-85 in the prevention of asthma in high-risk childreAsthmaRespiratory - AsthmaInflammatory and Immune System - Normal development and function of the immune system
ACTRN12612000518864Child Health Research Centre, University of Queensland60
Active, not recruiting
Not Applicable
A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in methotrexate-naïve patients with active rheumatoid arthritis.
EUCTR2005-002395-15-DEF. Hoffmann-La Roche Ltd.750
Active, not recruiting
Not Applicable
A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in methotrexate-naïve patients with active rheumatoid arthritis.Rheumatoid arthritisMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2005-002395-15-SEF. Hoffmann-La Roche Ltd.750
Active, not recruiting
Not Applicable
A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in methotrexate-naïve patients with active rheumatoid arthritis.Rheumatoid arthritisMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2005-002395-15-CZF. Hoffmann-La Roche Ltd.750
Active, not recruiting
Not Applicable
A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in methotrexate-naïve patients with active rheumatoid arthritis.Rheumatoid arthritisMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2005-002395-15-BEF. Hoffmann-La Roche Ltd.750